News for MediWound Ltd. (MDWD)

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care ma

Oppenheimer has initiated coverage on MediWound (MDWD), assigning it an Outperform rating and setting a price target of $34, slightly reduced from the previous

An analyst from H.C. Wainwright, Swayampakula Ramakanth, has increased the price target for MediWound (MDWD) from $25 to $31. The decision to maintain a Buy rat

Total Revenue: $4 million in Q1 2025, down from $5 million in Q1 2024.Gross Profit: $0.7 million with a gross margin of 19%, up from $0.6 million and a 12% mar

May 21, 2025 / 12:30PM GMTOperator Good day, and welcome to the MediWound first-quarter 2025 earnings call.(Operator instructions) Please note this event is bei

MediWound Ltd. (NASDAQ:MDWD) Q1 2025 Earnings Conference Call May 21, 2025 8:30 AM ETCompany ParticipantsDan Ferry - LifeSci AdvisorsOfer Gonen - CEOHani...

MediWound (MDWD) anticipates its revenue for the fiscal year 2025 to reach $24 million. This forecast is slightly above the average analyst expectation, which s

MediWound (MDWD) reported its first-quarter revenue at $4 million, falling short of the projected $5.2 million. The company has entered 2025 with continued conc

VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected b

New York-based Eyenovia, Inc. (EYEN) is up over 52 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

\nConference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time\n\nYAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd.

**media[614528]**

Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs

MediWound Ltd (MDWD) is set to release its Q4 2024 earnings on Mar 19, 2025. The consensus estimate for Q4 2024 revenue is $5.14 million, and the earnings are e

Q4 2024 Revenue: $5.8 million, up from $5.3 million in Q4 2023.Q4 2024 Gross Profit: $0.9 million with a gross margin of 15.5%, up from $0.7 million and a 13.5

Mar 19, 2025 / 12:30PM GMTOperator Good day, and welcome to MediWound's sports quarter and full year 2024 earnings conference call (Operator Instructions) Pleas

MediWound Ltd. (NASDAQ:MDWD) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ETCompany ParticipantsDan Ferry - IR, LifeSci AdvisorsOfer Gonen - Chief...

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now inc

**media[570626]**